Effects of diltiazem on serum lipids, exercise performance and blood pressure: Randomized, double-blind, placebo-controlled evaluation for systemic hypertension

Pool, Peter E.; Seagren, Shirley C.; Salel, Antone F.

doi:10.1016/0002-9149(85)90550-8

Cited by 89 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significant increase in serum HDL-C level was also observed after diitiazem administration. Pool et al (12) reported that administration of diltiazem is associated with a significant increase in levels of HDL-C, whereas other lipid parameters viz. TG, TC, VLDL-C and LDL-C did not show a decrease greater than 5% in magnitude.…”

Section: Resultsmentioning

confidence: 99%

A comparative study on the effects of Gemfibrozil, Diltiazem and Isosorbide dinitrate on lipid profile in patients of ischemic heart disease in India

Sharma

1997

Indian J Clin Biochem

View full text Add to dashboard Cite

Effects of three drugs, Gemfibrozil, Diltiazem and Isosorbide dinitrate (ISDN) on various lipid parameters were studied in patients with ischemic heart disease (IHD) with positive treadmill stress response. Gemfibrozil and diltiazem significantly lowered the levels of serum total lipids (TL), triglycerides (TG), phospholipids (PL), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL-C), and increased the levels of serum high density lipoprotein cholesterol (HDL-C) significantly. However, patients administered with ISDN showed a significant increase in all the lipid parameters except HDL-C, which showed a significant decrease.

show abstract

Section: Resultsmentioning

confidence: 99%

A comparative study on the effects of Gemfibrozil, Diltiazem and Isosorbide dinitrate on lipid profile in patients of ischemic heart disease in India

Sharma

1997

Indian J Clin Biochem

View full text Add to dashboard Cite

show abstract

“…Although the number of reports are limited, the calcium channel blockers nifedipine [13][14][15], diltiazem [14,16], verapamil [17,18], nicardipine [19], and nitrendipine [20] showed no adverse effect on serum lipoprotein metabolism. Among the effects of diltiazem on lipoproteins, Schulte et al showed [14] a decrease in LDL cholesterol and Pool et al showed [16] an increase in HDL cholesterol levels after diltiazem.…”

Section: Discussionmentioning

confidence: 99%

A multicenter comparison of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in patients with ischemic heart disease

Sasaki

Saeki

Kawasaki³

et al. 1992

Cardiovasc Drug Ther

View full text Add to dashboard Cite

The effects of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in 37 patients with ischemic heart disease were examined in a randomized, multicenter study. Nicorandil (n = 20, 10-40 mg/day, b.i.d.) and diltiazem (n = 17, 60-240 mg/day, b.i.d.) were administered for 12 weeks. Both nicorandil and diltiazem administration showed an effective antianginal effect. Diltiazem administration showed a significant hypotensive action. There were no significant changes in serum lipids, apolipoproteins, and lipoproteins for both nicorandil and diltiazem. There were no significant changes in body weight, uric acid, and fasting blood sugar levels during the test period for both drugs. These data show that nicorandil, like diltiazem, does not have any adverse effects on lipid metabolism and that it is a favorable drug to use as an agent for treating arteriosclerotic heart disease.

show abstract

“…The efficacy and the adequate duration of action of the sustained-release formulation of diltiazem, which was designed for the treatment of hypertension, has been documented in a number of studies [1][2][3][4][5][6]. However, it is the prompt-release formulation of diltiazem, which is used for the treatment of angina pectoris, which has become the most commonly prescribed cardiovascular drug in the United States.…”

Section: Discussionmentioning

confidence: 99%

“…concentrations, calcium antagonist Diltiazem, in a sustained-release (SR) capsule formulation designed for twice daily use [1][2][3][4][5][6], has recently been approved by the FDA for the treatment of hypertension. The prompt-release tablet formulation (three to four times/day), which has been available for the treatment of angina pectoris, has not been evaluated for efficacy in hypertension, except in one comparative study with hydrochlorothiazide [7].…”

mentioning

confidence: 99%

Antihypertensive monotherapy with tablet (Prompt-release) diltiazem: Multicenter controlled trials

Pool¹,

Nappi²,

Weber³

1990

Cardiovasc Drug Ther

Self Cite

View full text Add to dashboard Cite

The tablet formulation of diltiazem has been available for the treatment of angina pectoris but has not been comprehensively evaluated in hypertension. This study's aim was to evaluate the efficacy, dose-response characteristics, and duration of action of tablet (prompt-release) diltiazem in mild to moderate hypertension. Three placebo-controlled trials were designed. The first (trial #1) evaluated the dose response of 120, 240, and 360 mg/day (q12h regimen) of diltiazem in parallel fixed-dose fashion using hourly blood pressures. The second (trial #2) evaluated a q12h titration from 240 to 360 mg/day, which could be switched to q8h. The third (trial #3) evaluated a q8h titration from 180 to 270 to 360 mg/day, followed by conversion to a q12h regimen. The goal was a supine diastolic blood pressure of less than 90 mmHg and 10 mmHg less than baseline. With doses of diltiazem increasing from 120 to 240 to 360 mg/day, there was a progressive decrease in the average mean arterial pressure, describing a dose response with 120 mg/day as the ineffective dose. The peak effect for each dose regimen was found at 6 hours, with significant reductions lasting over 10 hours in the 240 mg/day and 360 mg/day groups. Peak plasma concentrations occurred at 3 hours. The residual effect at the trough of the 240 mg/day and 360 mg/day doses was 48% and 53% of the peak effect, respectively. When titration was carried out on a q8h regimen, both systolic and diastolic blood pressures were significantly decreased. When the regimen was switched from q8h to q12h, the effect was not maintained.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Effects of diltiazem on serum lipids, exercise performance and blood pressure: Randomized, double-blind, placebo-controlled evaluation for systemic hypertension

Cited by 89 publications

References 21 publications

A comparative study on the effects of Gemfibrozil, Diltiazem and Isosorbide dinitrate on lipid profile in patients of ischemic heart disease in India

A comparative study on the effects of Gemfibrozil, Diltiazem and Isosorbide dinitrate on lipid profile in patients of ischemic heart disease in India

A multicenter comparison of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in patients with ischemic heart disease

Antihypertensive monotherapy with tablet (Prompt-release) diltiazem: Multicenter controlled trials

Contact Info

Product

Resources

About